OCGN vs. LIFE, INBX, SANA, NMRA, DNA, VIR, CGEM, TARS, FDMT, and BCRX
Should you be buying Ocugen stock or one of its competitors? The main competitors of Ocugen include aTyr Pharma (LIFE), Inhibrx (INBX), Sana Biotechnology (SANA), Neumora Therapeutics (NMRA), Ginkgo Bioworks (DNA), Vir Biotechnology (VIR), Cullinan Therapeutics (CGEM), Tarsus Pharmaceuticals (TARS), 4D Molecular Therapeutics (FDMT), and BioCryst Pharmaceuticals (BCRX). These companies are all part of the "biological products, except diagnostic" industry.
aTyr Pharma (NASDAQ:LIFE) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership, community ranking and profitability.
aTyr Pharma has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Comparatively, Ocugen has a beta of 3.49, suggesting that its share price is 249% more volatile than the S&P 500.
61.7% of aTyr Pharma shares are held by institutional investors. Comparatively, 10.3% of Ocugen shares are held by institutional investors. 3.7% of aTyr Pharma shares are held by insiders. Comparatively, 3.5% of Ocugen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Ocugen had 7 more articles in the media than aTyr Pharma. MarketBeat recorded 10 mentions for Ocugen and 3 mentions for aTyr Pharma. Ocugen's average media sentiment score of 1.31 beat aTyr Pharma's score of 0.19 indicating that aTyr Pharma is being referred to more favorably in the media.
aTyr Pharma received 320 more outperform votes than Ocugen when rated by MarketBeat users. However, 68.92% of users gave Ocugen an outperform vote while only 61.52% of users gave aTyr Pharma an outperform vote.
Ocugen's return on equity of -56.92% beat aTyr Pharma's return on equity.
aTyr Pharma currently has a consensus target price of $23.67, indicating a potential upside of 1,268.02%. Ocugen has a consensus target price of $4.67, indicating a potential upside of 169.75%. Given Ocugen's higher probable upside, equities research analysts clearly believe aTyr Pharma is more favorable than Ocugen.
aTyr Pharma has higher earnings, but lower revenue than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.
Summary
aTyr Pharma beats Ocugen on 10 of the 16 factors compared between the two stocks.
Get Ocugen News Delivered to You Automatically
Sign up to receive the latest news and ratings for OCGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OCGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
